The DRAM Index high-leverage whale is only $2.7 away from liquidation, with $5.19 million in long positions on the verge of being liquidated.
BlockBeats news, June 29, according to reports, the DRAM index, which reflects spot memory prices, has seen a significant pullback at highs due to a spillover of storage sell-offs from South Korea, dropping about 6% in 4 hours and now reported at $70.68.
A whale (0x7b5) on the Hyperliquid platform opened a position at the beginning of the month, went long with 20x leverage, and continued to roll and increase the position, resulting in the liquidation price being above the average entry price. The liquidation line is at $68, only about 3.8% (about $2.7) away from the current price, with a position size of $5.2 million.
Among large position holders on the platform, the average on-chain long price is around $70.12, and the average short price is about $68.35. The notional size of short positions is about 2.35 times that of the longs, showing an overall bearish sentiment. The largest short is the “Storage Chain Short Leader” 0x4e23, who is heavily shorting the entire storage chain (also shorting Micron, SanDisk, and Western Digital), holding a $14.29 million DRAM short position with 6x leverage (average entry $77.73, opened on June 24). The current unrealized profit has reached $1.47 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like

The 160 Threshold Under Threat Again! Yen Nears "Intervention Red Line," Tokyo May Spend Money Again to Rescue the Currency
The Japanese yen is approaching the 1 USD = 160 JPY level. Atsushi Mimura commented that the movement is "too fast." The US-Japan interest rate gap may widen further, and Japanese officials have hinted at being ready to intervene again.
Blackstone (BX.US) injects up to $1.5 billion, providing fresh ammunition for Pfizer (PFE.US) in the weight-loss drug race
Pfizer announced on Wednesday that it has reached an agreement with Blackstone to obtain up to $1.5 billions in funding to support the development of its experimental monthly obesity treatment drug.
